Seattle Genetics, Inc. (SGEN): Price and Financial Metrics

Seattle Genetics, Inc. (SGEN)

Today's Latest Price: $192.34 USD

2.51 (-1.29%)

Updated Oct 29 4:00pm

Add SGEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

SGEN Stock Summary

  • Seagen Inc's market capitalization of $33,903,241,407 is ahead of 94.38% of US-listed equities.
  • With a one year PEG ratio of 841.94, Seagen Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 96.05% of US stocks.
  • With a price/sales ratio of 33.38, Seagen Inc has a higher such ratio than 94.62% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Seagen Inc are BGNE, MRVL, EA, XLNX, and CDNS.
  • SGEN's SEC filings can be seen here. And to visit Seagen Inc's official web site, go to

SGEN Stock Price Chart Interactive Chart >

Price chart for SGEN

SGEN Price/Volume Stats

Current price $192.34 52-week high $213.94
Prev. close $194.85 52-week low $90.57
Day low $189.02 Volume 787,300
Day high $196.10 Avg. volume 1,115,249
50-day MA $180.09 Dividend yield N/A
200-day MA $150.36 Market Cap 33.47B

Seattle Genetics, Inc. (SGEN) Company Bio

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.

SGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream

Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about Seattle Genetics Inc that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Th...

Benzinga | October 1, 2020

Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed

The charts and indicators of SGEN are looking healthy….SGEN

The Street RealMoney | October 1, 2020

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Patients had previously received a doublet chemotherapy and, if eligible, bevacizumab as fir

Business Wire | September 21, 2020

Seattle Genetics/Genmab antibody-drug conjugate shows positive effect in cervical cancer (NASDAQ:GMAB)

Genmab A/S (GMAB -1.3%) and development partner Seattle Genetics (SGEN -1.7%) announce positive results from a Phase 2 clinical trial, innovaTV 204, evalua

Seeking Alpha | September 21, 2020

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo -1.71%
3-mo 15.68%
6-mo 32.07%
1-year 79.09%
3-year 213.72%
5-year 363.58%
YTD 68.34%
2019 101.66%
2018 5.91%
2017 1.38%
2016 17.58%
2015 39.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8128 seconds.